New stent combo could shorten blood thinner use for major heart artery blockage
NCT ID NCT05650411
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a new type of stent (Supraflex Cruz) combined with a shorter course of blood thinners (only 1-3 months of dual therapy, then just one drug) for people with a blockage in the left main coronary artery. The goal is to see if this approach reduces bleeding risks while still preventing heart attacks and keeping the artery open. About 828 participants will be followed for two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Supraflex Cruz stent (drug-eluting stent with sirolimus) and P2Y12 inhibitor (ticagrelor or prasugrel) single antiplatelet therapy
- What this could lead to
- If successful, this could offer a safer, effective way to treat left main coronary artery disease with a shorter course of blood thinners, reducing bleeding risks.
- What could go wrong
- This is an early-stage trial with no phase designation, and the strategy has not been tested in this high-risk group before. There is a risk of heart attack or stent blockage despite the new approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEFT MAIN CORONARY ARTERY STENOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zurich University Hospital
RECRUITINGZurich, Canton of Zurich, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.